Scientific recommendation on classification of advanced therapy medicinal products

Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency.

It is stressed that the scientific recommendation on advanced therapy classification does not amount to any endorsement of the plausibility of the product, including the mode of action or therapeutic indication(s) claimed by the applicant.

Brief description (or name when available) of the active substance(s)

*In vitro* transcribed mRNA sequences encoding six non-small cell lung cancer (NSCLC) associated antigens.

Brief description of the finished product

Powder and solvent for solution for injection.

Proposed indication

Treatment of non-small cell lung cancer.

EMA/CAT conclusion

The procedure was finalised on 27 January 2017 for the following recommendation.

On the basis that the product:
• contains an active substance that consist of a set of different recombinant nucleic acid molecules of biologic origin, namely the coding sequences of the human NSCLC associated antigens;
• is intended to be administered to human beings with a view to adding genetic sequences;
• its therapeutic effect relates directly to the product of genetic expression of these sequences,

the EMA/CAT considers that the Product falls within the definition of a gene therapy medicinal product as provided in Article 2(1) of Regulation (EC) 1394/2007.